ArticleNLR pyrin domain 3 (NLRP3) protein expression in juvenile systemic lupus erythematosus and lupus nephritis
ArticleNLR pyrin domain 3 (NLRP3) protein expression in juvenile systemic lupus erythematosus and lupus nephritis
ArticleSerum interleukins 2 and 10 in juvenile systemic lupus erythematosus: relation to disease activity
ArticleSerum interleukins 2 and 10 in juvenile systemic lupus erythematosus: relation to disease activity
ArticleSerum survivin expression in systemic-onset juvenile idiopathic arthritis in relation to disease activity and macrophage activation
ArticleSerum survivin expression in systemic-onset juvenile idiopathic arthritis in relation to disease activity and macrophage activation
ArticleSerum level of Interleukin-33 and relation to disease activity in Juvenile Idiopathic Arthritis
ArticleSerum level of Interleukin-33 and relation to disease activity in Juvenile Idiopathic Arthritis
ArticleOutcomes of Tocilizumab on the Disease Activity in Children with Juvenile Idiopathic Arthritis
ArticleOutcomes of Tocilizumab on the Disease Activity in Children with Juvenile Idiopathic Arthritis
ArticleSerum interleukin-17 expression in a group of Egyptian patients with juvenile systemic lupus erythematosus
ArticleSerum interleukin-17 expression in a group of Egyptian patients with juvenile systemic lupus erythematosus
ArticleASSESSMENT OF 14-3-3 PROTEIN ETA AND ANTI-CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP) IN JUVENILE IDIOPATHIC ARTHRITIS VERSUS ADULT ONSET RHEUMATOID ARTHRITIS
ArticleASSESSMENT OF 14-3-3 PROTEIN ETA AND ANTI-CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP) IN JUVENILE IDIOPATHIC ARTHRITIS VERSUS ADULT ONSET RHEUMATOID ARTHRITIS